HTL to cooperate with Chiesi Group to support the commercialization of HTL’s lipid molecule product October 12, 2009
Posted by israelhealthcare in Lipid molecule, Uncategorized.Tags: Chiesi Group, emulsion, fatty acids, High Tech Lipids, Lipid molecule, Misgav Venture Accelerator
add a comment
Lipid molecule developer High Tech Lipids (HTL) has signed a cooperation agreement with European pharmaceutical company Chiesi Group, to support the development, regulatory procedure and commercialization of HTL’s first product, an innovative lipid emulsion optimized for intravenous feeding of preterm neonates.
HTL has developed an innovative emulsion that is optimized for intravenous feeding. The emulsion is based on a new model of engineered triglycerides and a unique profile of fatty acids. The company is currently making preparations to begin pre-clinical testing. The market potential for HTL products in infants and adults is about $2 billion worldwide.
”The agreement with HTL is a strategic choice for the development of our neonatology portfolio,” stated Dr. Paolo Chiesi, Chiesi Group Vice President and R&D Director. “We are confident that, once fully developed and registered, this innovative lipid emulsion will significantly contribute to the improvement of clinical nutrition of preterm newborns. The deal with HTL confirms the Chiesi Group’s commitment to developing new therapeutic solutions for rare diseases”.
HTL, which started with Misgav Venture Accelerator, has developed a new lipid molecule that is an advanced solution to the problem of intravenous lipid infusions. It will prevent severe side effects and meet all of the premature infant’s nutritional needs. HTL was founded in 2004 by Dr. Geila Rozen and Irit Shochat, together with Dr. Sobhi Basheer, an internationally renowned chemist specialising in enzymatic processing of lipids.
The Chiesi Group is a research-focused international company developing added-value innovative pharmaceutical solutions to improve the quality of human life. Founded in Parma in 1935, Chiesi today operates globally through 23 direct affiliates, 3 manufacturing sites and 4 research laboratories (in Italy, France, the UK and the US).
Sponsored Links – Baby skin Care Ointment | Compression Therapy Device
SteadyMed raised $2 million in funding round led by Samson Venture Partners January 29, 2009
Posted by israelhealthcare in Uncategorized.Tags: Drug Delivery
add a comment
Medical device startup SteadyMed closed a $2 million round of funding led by Samson Venture Partners, the investment management arm of Becker & Associates Consulting, an FDA consulting firm in Washington, DC specializing in innovative medical devices and drugs. Prior investors in SteadyMed include the RAD Biomed Incubator, and its Chairman, Yehuda Zisapel.
SteadyMed, founded in 2005, develops sophisticated miniature disposable infusion pumps with unique drug delivery characteristics that provide enhanced portability and optimized infusion algorithms for large molecules and high-viscosity drugs. The Company is targeting interest from several major pharma companies having biological drugs requiring the specialized drug-delivery characteristics enabled by the PatchPump technology.
“The SteadyMed drug delivery platform has the potential to expand the market for currently approved drugs, and, perhaps most importantly, create markets that do not yet exist for new molecular entities, especially certain biologics,” said Karen M. Becker, CEO of Becker & Associates Consulting and Chair of the Samson Investment Committee.
Based in Tel Aviv, Israel, SteadyMed is developing innovative devices for delivering injectable therapeutic drugs for chronic conditions. The company is managed by Yossi Aldar, who was previously the Managing Director of Versamed Medical Systems and before that the CEO and co-founder of Flight Medical.
Sponsored Links – Brain Fitness for Adults | Dynamic Single Cell Monitoring
Dune Medical closed $12.5 million second round of venture financing led by Apax Partners June 29, 2006
Posted by israelhealthcare in Medical Device, Uncategorized.Tags: lumpectomy procedure, surgical oncology
add a comment
Israeli medical device company, Dune Medical, has closed a $12.5 million second round of venture financing led by Apax Partners who invested $11.5 million in the round. Apax also led the $7.5 million first round which closed in 2004. This funding will be used to complete pivotal U.S. clinical studies of Dune’s BP probe and console system, attain market clearance of the BP system in the U.S. by the Food & Drug Administration (FDA).
Dune has also received the European Union CE Marking designation for its disposable BP probe and console system. The intended use for the probe and system is to enable intraoperative, on-contact measurement of suspected tissue surfaces during a lumpectomy (partial mastectomy) procedure. The CE mark permits Dune to market its device throughout the European Union.
“The Dune BP probe and console system will enable surgical oncology teams to consistently obtain cleaner margins during the initial procedure,” said Amos Goren from Apax Partners and director of Dune’s board. “This has the potential to drastically reduce the disturbingly high rate of re-excisions, and there is a particularly noteworthy need for this especially in breast cancer.”
Headquartered in Ceasarea, Israel and founded in 2002, Dune Medical Devices is engaged in the development and commercialization of devices for real time tissue characterization. Dune’s first commercial product is a disposable hand-held device that facilitates complete tumor removal. The device will be used by surgeons performing lumpectomies in order to assess tumor margin in real time.
Sponsored Links – Chronic Venous Insufficiency Treatment
| Homecare Monitoring Solution
